tymelogo.jpg
Syros and Tyme Technologies Announce Stockholder Approval of Merger
September 15, 2022 16:13 ET | TYME Technologies, Inc.
-- Combined Company to Trade on Nasdaq Under Ticker “SYRS” ---- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- CAMBRIDGE, Mass. and BEDMINSTER, N.J., Sept. 15, 2022 (GLOBE...
tymelogo.jpg
TYME Technologies, Inc. Announces Proxy Advisory Firms Glass Lewis and ISS Recommend Stockholders Vote “FOR” Proposed Merger of Syros and Tyme
September 07, 2022 08:00 ET | TYME Technologies, Inc.
BEDMINSTER, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the “Company”), today announced that independent proxy advisory firms Glass, Lewis & Co....
tymelogo.jpg
TYME Technologies, Inc. Reports Fourth Fiscal Quarter and Full Year 2022 Financial and Operating Results
May 25, 2022 07:15 ET | TYME Technologies, Inc.
BEDMINSTER, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies...
tymelogo.jpg
TYME Technologies, Inc. Announces Exploration of Strategic Options
March 29, 2022 06:50 ET | TYME Technologies, Inc.
BEDMINSTER, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies...
tymelogo.jpg
TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022
March 09, 2022 06:50 ET | Tyme Technologies, Inc.
-- Preclinical results from Georgetown University support that SM-88 is potentially a novel anti-cancer agent in drug resistant estrogen receptor positive breast cancer -- -- Poster presentation...
tymelogo.jpg
TYME Announces Third Quarter Fiscal 2020 Financial and Operating Results
February 05, 2020 08:00 ET | Tyme Technologies, Inc.
Strategic collaboration with Eagle Pharmaceuticals entitles TYME to receive up to a total of $40 million, which included $20 million upfront already received and $20 million in potential milestone...
tymelogo.jpg
Health Economic Research Study Demonstrates Increased Use of New Medicines in the Treatment of Patients with Pancreatic Cancer Reduces Total Cost of Care
January 27, 2020 08:00 ET | Tyme Technologies, Inc.
The study shows that for every additional $1 spent on innovative medicines for pancreatic cancer between 2009 to 2016, there was a reduction in non-medicine spending of $8 to $9  This preliminary...
tymelogo.jpg
TYME and The Joseph Ahmed Foundation Announce First Patient Dosed in Phase II (HopES) Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with High-Risk Sarcomas
January 16, 2020 08:00 ET | Tyme Technologies, Inc.
New oral approach aimed at disrupting cancer metabolism in high-risk sarcomas; 12,000 cases annually in U.S. aloneOral SM-88 represents a new approach designed to selectively disrupt protein synthesis...
tymelogo.jpg
TYME Announces First Patient Dosed in TYME-88-Panc Pivotal Trial to Evaluate SM-88 as Oral Treatment for Patients with Metastatic Pancreatic Cancer
January 08, 2020 08:00 ET | Tyme Technologies, Inc.
Oral SM-88 represents a new approach designed to selectively disrupt protein synthesis in cancers - demonstrated responses in 15 different cancer types across four separate studiesData presented at...
tymelogo.jpg
Tyme Technologies to Present at the 2019 Cross-Border Healthcare Winter Summit in New York
December 04, 2019 08:00 ET | Tyme Technologies, Inc.
NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...